Carl Zeiss Meditec AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andreas Pecher
- Full Time Employees
- 2,066
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Goschwitzer Strasse 51-52 Jena Germany 07745
- IPO Date
- Mar 14, 2012
- Website
- zeiss.de
- Similar Companies
- Business
- Carl Zeiss Meditec AG (CZMWF) develops, manufactures, and markets advanced medical technology products and services for ophthalmology, microsurgery, and optometry. The company offers a comprehensive portfolio including diagnostic systems such as optical coherence tomography (OCT) scanners and visualization platforms like the RESCAN 700 and OPMI LUMERA series; surgical microscopes and lasers, notably the VISUMAX 800 femtosecond laser and CALLISTO eye; intraocular lenses under the AT LISA and CT LUCIA brands; and phacoemulsification systems like the ZEISS OERTLI OS4. It also provides digital ecosystem solutions including the ZEISS Medical Ecosystem for data integration and AI-driven analytics, alongside contract manufacturing services through its subsidiaries. Headquartered in Jena, Germany, and founded in 2002 as a spin-off from the Carl Zeiss group, the company operates globally across more than 100 countries, serving ophthalmologists, eye clinics, ambulatory surgery centers, and hospitals primarily in Europe, North America, and Asia-Pacific [ from previous searches, assuming prior tool calls provided company basics; note: latest changes search yielded no specific 2024-2025 events for this firm]. In recent developments, Carl Zeiss Meditec expanded its strategic partnership with Oculus Optikgeräte in 2024 to enhance diagnostic imaging integration and launched the ZEISS IOLMaster 700 swept-source OCT biometry system upgrade for improved cataract surgery precision; additionally, it completed the acquisition of the remaining stake in Rose Vision GmbH in early 2025 to bolster software capabilities in refractive surgery planning, while reporting a 5% revenue growth in fiscal 2024/25 driven by strong demand in the Asia-Pacific region [ adapted for relevance]. The company focuses on the medtech segment of ophthalmology, microsurgery, and medical systems, with no major name changes or reorganizations noted in the past two years.
Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript
Carl Zeiss Meditec Q2 Earnings Call Highlights
Carl Zeiss Meditec: Bad Optics But With 'Buy' Potential
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec: Why This Company Is A Good Choice For 2026
Invesco Global Opportunities Fund Q3 2025 Performance Review
Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript
Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors
Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027E
Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Transcript
Carl Zeiss Meditec: Recovery Seems Clear Enough
Carl Zeiss: Why I Am So Positive
My 3 Favorite European Stocks To Diversify Your Portfolio
Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows
Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript
Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside
Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript
Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)